All In Biotech

NDA 021342 · Cediprof INC

Levo-T

Levothyroxine Sodium · Oral

Last checked: Nov 20, 2026Latest source record: May 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Mar 1, 2002

Approved uses

4

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

101,597

70,397 serious, 8,379 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7) and Overdosage (10)]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including levothyroxine sodium tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily...

What it is approved for

From the label in effect Jun 23, 2026.

Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 9, 2011 Supplement 20 · Efficacy Letter
  • Jun 23, 2004 Supplement 4 · Efficacy ReviewLetter
  • Jun 23, 2004 Supplement 3 · Efficacy ReviewLetter
  • Mar 1, 2002 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLabelLetter
12 products under this application
  • LEVO-T · LEVOTHYROXINE SODIUM 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVO-T · LEVOTHYROXINE SODIUM 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue8,318
  • nausea7,282
  • diarrhoea6,612
  • headache6,426
  • dyspnoea6,344
  • drug ineffective5,446
  • pain5,349
  • dizziness5,094
  • vomiting4,552
  • asthenia4,372
  • off label use4,143
  • fall4,135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,043
20052,018
20062,180
20072,759
20084,015
20093,823
20104,305
20116,146
20126,819
20131,398
20141,713
20152,374
20163,138
20173,607
20184,138
20194,005
20205,441
20215,801
20227,387
20236,969
20247,345
20258,275
20265,897

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Levo-T (Levothyroxine Sodium)

2024 spending

$179K

Beneficiaries

2,674

9,029 claims

Per beneficiary

$67

$0.41 per unit

View as table
YearSpending
2020$685,531
2021$351,244
2022$234,322
2023$240,983
2024$178,791

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 611 on PubMed

Sponsor: Cediprof INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.